Journal of Drugs in Dermatology articles from December 2007

Journal of Drugs in Dermatology archives from December 2007

Erratum.(Correction notice)
December 1, 2007... In the October 2007 issue, Restylane's FDA indication was mislabeled in the Aesthetic Practice Trends column on What's New with Hyaluronic Acid Fillers. Its correct FDA indication is for mid-to-deep dermal implantation for the correction of...

Letter from the editor-in-chief.
December 1, 2007... The Future of Mohs Surgery The greatest advancement in the treatment of skin cancers has been the development of Mohs surgery. Since its inception over 50 years ago, hundreds of thousands of patients with skin cancer have been treated...

Issues affecting specialty career paths in dermatology.(Report)
December 1, 2007... Abstract As the field of medicine changes, physicians deal with ever-increasing challenges and pressures. An overview of broad career paths within the specialty of dermatology is presented and important issues affecting these subspecialty...

Pulsed dye laser for the treatment of hypergranulation tissue with chronic ulcer in postsurgical defects.
December 1, 2007... Abstract Background and Objective: Hypergranulation tissue may complicate postoperative wounds, causing them to become chronic nonhealing ulcers. There is no reliably effective treatment. We report the use of the 595-nm pulsed-dye laser...

Topical photodynamic therapy for dermatologic disorders: results and complications.
December 1, 2007... Abstract Background: Topical photodynamic therapy (PDT) involves the use of a photosensitizing topical medication that is activated by a light source in the presence of oxygen leading to cellular destruction and subsequent...

Duration of remission of biologic agents for chronic plaque psoriasis.
December 1, 2007... Abstract Background: The efficacy of biologic agents to treat psoriasis has been established in well-designed clinical trials. The primary endpoint is usually a 75% reduction from the baseline Psoriasis Area and Severity Index, stressing...

Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy.
December 1, 2007... Abstract Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of skin and subcutaneous tissue. The current accepted theory is that PG is an immunologic-based phenomenon. Several therapies have been used to control this disease,...

New onset flushing due to unauthorized substitution of niacin for nicotinamide.(CASE REPORTS)
December 1, 2007... Abstract Nicotinamide is the amide form of niacin and has anti-inflammatory properties that have led to its use in the treatment of several inflammatory dermatologic conditions, such as rosacea. Niacin has established its role in the...

Type I hypersensitivity to lidocaine.(CASE REPORTS)
December 1, 2007... Abstract Lidocaine hydrochloride is the most commonly used anesthetic agent in dermatology. Despite its widespread and frequent use, adverse reactions to lidocaine are uncommon. The majority of side effects include vasovagal reactions and...

Practical experience with efalizumab in hand and foot psoriasis.(CASE REPORTS)
December 1, 2007... Abstract Psoriasis of the hands and feet is highly debilitating and difficult to treat. It may be of a plaque-or pustular-type, or a combination of the two. Efalizumab (Raptiva[R], Genentech Inc), a humanized monoclonal antibody that...

Minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy.(CASE REPORTS)
December 1, 2007... Abstract Although disfiguring hyperpigmentation is a well-defined complication of minocycline therapy, modalities to reverse the phenomenon are unpredictable. We report a case of minocycline-induced, blue-black pigmentation in a...

Tissue tightening: a hot topic utilizing deep dermal heating.(AESTHETIC PRACTICE TRENDS)
December 1, 2007... Aesthetic Practice Trends is a periodic feature that will give readers updates on topics involving everyday clinical practice issues from how to run a successful dermatology practice to marketing and advertising ideas, and trends. It will also...

Update on pemphigus treatment: present and future.(NEWS, VIEWS, AND REVIEWS)
December 1, 2007... Abstract The life-saving management of pemphigus requires extended use of systemic therapies. Presently, there is no standard treatment for pemphigus, and each therapeutic approach carries potential benefits and risks. Recently published...

Nodular basal cell carcinoma: when in doubt, cut it out.(NEWS, VIEWS, AND REVIEWS)
December 1, 2007... Abstract Treating superficial basal cell carcinomas (BCCs) with photodynamic therapy or topical imiquimod can provide effective results in situations where an excisional approach is contraindicated or undesirable. Numerous studies have...

Forodesine HCl for cutaneous T cell lymphoma.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... BioCryst Pharmaceuticals, Inc recently announced that patient enrollment has begun for its clinical trial of forodesine HCl in the treatment of cutaneous T cell lymphoma (CTCL). Forodesine HCl is an analog inhibitor of the enzyme purine...

Ceftobiprole for diabetic foot infections.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... Johnson & Johnson Pharmaceutical Research & Development, LLC recently reported results from a phase II trial that examined ceftobiprole, a cephalosporin antibiotic, in the treatment of diabetic foot infections. The multicenter, double-blind...

Phase I wound healing trial.(PIPELINE PREVIEWS)(CardioVascular BioTherapeutics, Inc)(Brief article)
December 1, 2007... CardioVascular BioTherapeutics, Inc recently announced it has completed its phase I clinical trial that studied wound healing with its protein-based drug candidate, CVBT-141B, formulated with human fibroblast growth factor-1 (FGF-1). The...

Hyphanox[TM] for onychomycosis.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... A phase III clinical trial of Hyphanox for the treatment of toenail onychomycosis has recently completed the enrollment of 1,370 patients. Hyphanox is a patented oral formulation of itraconazole developed by Barrier Therapeutics. The clinical...

Incyclinide for rosacea.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... CollaGenex Pharmaceuticals, Inc recently announced the results from its phase II dose-finding study for incyclinide for the treatment of rosacea. The double-blind, placebo-controlled trial included 197 patients with moderate to severe rosacea...

FDA approval for Lamisil[R] Oral Granules.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... Novartis Pharmaceuticals Corporation recently announced that it has received FDA approval for a new oral formulation of Lamisil (terbinafine hydrochloride) for the treatment of tinea capitis in patients 4 years of age and older. Lamisil Oral...

Cloderm[R] and decreased allergic contact dermatitis.(PIPELINE PREVIEWS)(Brief article)
December 1, 2007... Results of a recent study indicated that Cloderm (clocortolone pivalate) Cream 0.1% has the lowest possibility of inducing an allergic contact dermatitis (ACD) as compared to other mid-potency topical steroids. The study evaluated 39 patients...

A review of the new antifungals: posaconazole, micafungin, and anidulafungin.(SCHOOLS OF PHARMACOLOGY)
December 1, 2007... Abstract This column reviews 3 new systemic antifungal agents (posaconazole, micafungin, and anidulafungin) from the standpoint of dermatology. Posaconazole, approved to treat invasive Aspergillus and Candida infections, is available in an...

EpiCream[R] versus Elidel[R] for treatment of mild to moderate atopic dermatitis.(ATOPIC DERMATITIS)(Ceragenix Pharmaceuticals)(Brief article)
December 1, 2007... Sponsored by Ceragenix Pharmaceuticals. The objective of this study is to determine whether Epicream is a safe and effective therapy for mild to moderate atopic dermatitis and whether it may serve as an alternative to Elidel therapy. ...

The effects of probiotics in atopic dermatitis.(ATOPIC DERMATITIS)(Los Angeles and Thrasher Research Fund)(Brief article)
December 1, 2007... Sponsors and Collaborators: University of California, Los Angeles and Thrasher Research Fund. The purpose of this study is to study the clinical effects of taking probiotics in patients who have moderate to severe atopic dermatitis. ...

A study of the safety and efficacy of JNJ-26113100 in the treatment of adult atopic dermatitis.(ATOPIC DERMATITIS)(Brief article)
December 1, 2007... Sponsored by Alza Corporation. The purpose of this study is to evaluate the safety and effectiveness of oral administration of 4 dose regimens of JNJ-26113100 prepared in a capsule formulation administered for 6 weeks in the treatment of adult...

Imiquimod in children with plaque morphea.(CONNECTIVE TISSUE DISORDERS)(Brief article)
December 1, 2007... Sponsored by The Hospital for Sick Children. The purpose of this study is to assess the potential efficacy and relative safety of imiquimod in children with plaque morphea. Condition Intervention Phase Scleroderma,...

UVA1 light for scleroderma and similar conditions.(CONNECTIVE TISSUE DISORDERS)(Brief article)
December 1, 2007... Sponsored by University of Michigan. The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin. Condition Intervention Keloid ...

Treatment of cutaneous lupus erythematosus with the 595-nm flashlamp pulsed dye laser.(CONNECTIVE TISSUE DISORDERS)(Brief article)
December 1, 2007... The purpose of using the 595-nm Vbeam Perfecta[TM] flashlamp-excited, pulsed dye laser in this study is to help improve skin disease. Condition Intervention Phase Cutaneous Lupus Procedure: laser treatment...

Pilot investigation of a multi-nutrient supplement on skin aging and aging metabolites in healthy women.(PHOTOAGING)(Brief article)
December 1, 2007... Sponsors and Collaborators: Stanford University and NuSkin. The purpose is to determine if multi-nutrient supplementation affects visible signs of skin aging as well as blood measurements of aging. We are seeking smokers and nonsmokers. ...

Single-blind study determining the efficacy of polypodium leucotomos extract supplement in decreasing UVA premutagenic and photoaging markers (Heliocare[R]).(PHOTOAGING)(Brief article)
December 1, 2007... Sponsored by University of Miami. The purpose of this study is to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of...

A study to evaluate psoriasis outcomes and safety events in patients with chronic moderate to severe plaque psoriasis (response).(PSORIASIS)(Brief article)
December 1, 2007... Sponsored by Genentech. This is a multicenter, prospective, 5-year surveillance study of approximately 5,000 Raptiva[R]-treated patients and approximately 500 non-Raptiva treated patients (formerly 2,500 comparison patients who were treated...

A study of the safety and effectiveness of CNTO 1275 compared to etanercept for the treatment of moderate to severe plaque psoriasis.(PSORIASIS)(Brief article)
December 1, 2007... Sponsored by Centocor, Inc. The purpose of this research study is to compare the effects (good and/or bad) of CNTO 1275 or etanercept on moderate to severe plaque psoriasis. Condition Intervention Phase Psoriasis...

T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.(SKIN CANCER)(Brief article)
December 1, 2007... Sponsors and Collaborators: Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham and National Cancer Institute (NCI). The purpose of this randomized phase II trial is to study how well T4N5 liposomal lotion works in...

Optical imaging of skin cancers for margin delineation of nonmelanoma skin cancers.(SKIN CANCER)(Brief article)
December 1, 2007... Sponsors and Collaborators: M.D. Anderson Cancer Center and National Institute of Dental and Craniofacial Research (NIDCR). The primary objective of this exploratory laboratory study is to evaluate the ability of optical imaging technologies...

Photodynamic therapy using silicon phthalocyanine 4 in treating patients with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.(SKIN CANCER)(Brief article)
December 1, 2007... Sponsors and Collaborators: Case Comprehensive Cancer Center and National Cancer Institute (NCI). This phase I trial is studying the side effects and the best dose of photodynamic therapy using silicon phthalocyanine 4 in treating patients with...

Topical tazarotene in treating patients with basal cell skin cancer and basal cell nevus syndrome.(SKIN CANCER)(Children's Hospital & Research Center Oakland)(National Cancer Institute )(Brief article)
December 1, 2007... Sponsors and Collaborators: Children's Hospital & Research Center Oakland and National Cancer Institute (NCI). This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and...

Difluoromethylornithine (DFMO) chemoprevention of skin cancer in organ transplant recipients.(SKIN CANCER)(Brief article)
December 1, 2007... Sponsored by University of Wisconsin. The specific aims are to determine if DFMO at 500 mg daily will be well tolerated for 12 months and not affect organ transplant viability, will inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced...

Dasatinib in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma.(SKIN CANCER)(National Cancer Institute )(Brief article)
December 1, 2007... Sponsors and Collaborators: Yale University and National Cancer Institute (NCI). This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma. ...

Famciclovir pediatric formulation in children 1 to 12 years of age with herpes simplex infection.(SKIN INFECTION)(Brief article)
December 1, 2007... Sponsored by Novartis. This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir[R] in children 1-12 years of age. Condition Intervention Phase Herpes Simplex Drug: Famvir...

Topical 5-ALA photodynamic therapy for the treatment of verruca vulgaris.(SKIN INFECTION)(Brief article)
December 1, 2007... Sponsored by National Taiwan University Hospital. The purpose of this clinical trial is to develop topical ALA-PDT as an alternative treatment of wart but without the unwanted side effects of pain and burning. Condition Warts ...

Study comparing the safety and efficacy of tigecycline with ampicillin-sulbactam or amoxicillin-clavulanate to treat skin infections.(SKIN INFECTION)(Brief article)
December 1, 2007... Sponsored by Wyeth. The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavutanate in the treatment of a complicated skin and/or skin...

Study evaluating the safety and efficacy of a once-daily dose of tigecycline vs ertapenem in diabetic foot infections.(SKIN INFECTION)(Brief article)
December 1, 2007... Sponsored by Wyeth. This purpose of this study is to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. Condition Intervention ...

Efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride versus 5% amorolfine nail lacquer in patients with mild to moderate toenail onychomycosis.(SKIN INFECTION)(Brief article)
December 1, 2007... Sponsored by Novartis. This study will evaluate the efficacy, safety, and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail...